People with chronic obstructive pulmonary disease exacerbations prefer early discharge, then treatment at homeBMJ 2019; 364 doi: https://doi.org/10.1136/bmj.k5339 (Published 19 February 2019) Cite this as: BMJ 2019;364:k5339
- Rob Cook, clinical director1,
- Vaughan Thomas2,
- Rosie Martin, clinical specialist1
- on behalf of the NIHR Dissemination Centre
- 1Bazian, Economist Intelligence Unit healthcare, London, UK
- 2Wessex Institute, University of Southampton, Southampton, UK
- Correspondence to R Cook
Home treatment of COPD exacerbation selected by DECAF score: a non-inferiority, randomised controlled trial and economic evaluation
Echevarria C, Gray J, Hartley T, Miller J, Simpson AJ, Gibson GJ, Bourke SC
Published on 24 April 2018 Thorax 2018;73:713-22
This project was funded by the National Institute for Health Research—Research for Patient Benefit Programme (project number PB-PG-0213-30105).
To read the full NIHR Signal, go to: https://discover.dc.nihr.ac.uk/content/signal-000691/hospital-at-home-treatment-for-copd-flare-ups
Competing interestsThe BMJ has judged that there are no disqualifying financial ties to commercial companies. The authors declare the following other interests: none.
Further details of The BMJ policy on financial interests is here: https://www.bmj.com/about-bmj/resources-authors/forms-policies-and-checklists/declaration-competing-interests
Contributors All authors contributed to development and review of this summary, as part of the wider NIHR Signals editorial team (https://www.bmj.com/NIHR-signals). RC is guarantor.
Disclaimer NIHR Signals are owned by the Department of Health and Social Care and are made available to the BMJ under licence. NIHR Signals report and comment on health and social care research but do not offer any endorsement of the research. The NIHR assumes no responsibility or liability arising from any error or omission or from the use of any information contained in NIHR Signals.
Permission to reuse these articles should be directed to.